SCHEMBL6284740

SCHEMBL6284740

C/C(=N/NC(=N)N)c1cn(S(C)(=O)=O)c2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 4/20 0.43
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PLK1 P53350 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HTR6 P50406 1/20 0.39
PLK4 O00444 1/20 0.37
CHEK1 O14757 1/20 0.37
AURKA O14965 1/20 0.37
CHUK O15111 1/20 0.37
DAPK3 O43293 1/20 0.37
JAK2 O60674 1/20 0.37
ROCK2 O75116 1/20 0.37
PAK4 O96013 1/20 0.37
CHEK2 O96017 1/20 0.37
CDK1 P06493 1/20 0.37
PIM1 P11309 1/20 0.37
PRKACA P17612 1/20 0.37
FGFR3 P22607 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284744 1.00 HTR3A (0.43) HTR3ALMNASMN1; SMN2PLK1MEN1
SCHEMBL6286909 0.87 LMNA (0.60) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6286906 0.87 LMNA (0.60) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6284673 0.87 LMNA (0.51) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6284670 0.87 LMNA (0.51) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6287562 0.84 HTR6 (0.46) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6285310 0.84 HTR6 (0.54) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6285302 0.84 HTR6 (0.54) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6287560 0.84 HTR6 (0.46) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6281765 0.84 KDM1A (0.36) HTR3ALMNASMN1; SMN2PLK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A HTR3A 11/4885LMNA 4212/4885SMN1; SMN2 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.